Traws Pharma announces antiviral program targeting Hantavirus and Ebola outbreaks

Traws Pharma, Inc.

Novel dual-strike combination agent exploits host nucleotide depletion and forced incorporation to halt viral replication.
Non-clinical development advancing in BSL-3/4 labs; plans to engage CDC, NAFDAC, and AMA for fast-track development.
Company scaling chemical manufacturing to enable immediate supply and potential stockpiling for health agencies.
Former CDC head Dr. Robert Redfield appointed CMO; CEO Iain Dukes highlights rapid response capabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.